# A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)

Source: https://onco.cc/trials/nct05652686/  
OnCo record `nct05652686` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Peluntamig, Carboplatin, Etoposide in small-cell lung cancer and prostate cancer, run by Phanes Therapeutics, now recruiting.

## Summary

A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study) is a phase 1/2 interventional study registered as NCT05652686 by Phanes Therapeutics, with 203 participants planned, started 2023-09-05 and due to reach its primary completion in 2027-12. Interventions recorded: Peluntamig (PT217), Carboplatin + Etoposide, Paclitaxel., Atezolizumab, Lurbinectedin. Conditions listed: Small Cell Lung Cancer (SCLC), Large Cell Neuroendocrine Cancer (LCNEC), Neuroendocrine Prostate Cancer (NEPC), Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC). No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05652686
- Phase: 1/2
- Setting: An Open-label, Multicenter, Dose Escalation, and Dose Expansion Phase 1/2 Study With Peluntamig (PT217) Followed by a Key ChemotherapY and/or Checkpoint Inhibitor ComBination in Patients With NeuRoendocrIne Carcinomas That Are Known to be DLL3 expressinG CancErs (SKYBRIDGE)
- Sponsor: Phanes Therapeutics
- Enrolled: 203

## Sources

- ClinicalTrials.gov NCT05652686: https://clinicaltrials.gov/study/NCT05652686

## Connected records

- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Atezolizumab](https://onco.cc/drugs/atezolizumab/), [Carboplatin](https://onco.cc/drugs/carboplatin/), [Etoposide](https://onco.cc/drugs/etoposide/), [Lurbinectedin](https://onco.cc/drugs/lurbinectedin/), [Paclitaxel / nab-paclitaxel](https://onco.cc/drugs/paclitaxel/), [Peluntamig](https://onco.cc/drugs/peluntamig/)

---
JSON: https://onco.cc/api/v1/entities/nct05652686.json